Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 10:00 ET | Source: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...
May 02, 2023 07:00 ET | Source: Immatics N.V.

Immatics veröffentlicht klinisches Daten-Update aus laufender Phase-1b-Zelltherapie-Studie mit ACTengine® IMA203 TCR-T-Monotherapie in Kohorte A gegen die Zielstruktur PRAME

Live-Webcast am Dienstag, den 2. Mai, um 14:30 Uhr MESZ Update umfasst Daten von 11 stark vorbehandelten Patienten nach Letztlinientherapie in der Phase-1b-Dosisexpansionskohorte A, die mit der...
May 02, 2023 07:00 ET | Source: https://immatics.com/

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203...
September 03, 2020 07:00 ET | Source: Immatics N.V.

Immatics veröffentlicht Ergebnisse des zweiten Quartals 2020 sowie Informationen zur Geschäftsentwicklung

Tübingen, Deutschland und Houston, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Abschluss der Fusion mit ARYA Life Science Acquisition Corp. sowie anschließende Börsennotierung an der NASDAQ im...
September 03, 2020 07:00 ET | Source: https://immatics.com/

Immatics Announces Second Quarter 2020 Financial Results and Business Update

Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction...
August 06, 2020 07:00 ET | Source: https://immatics.com/

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth

Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGMP...